^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SPTA1 mutation

    i
    Other names: SPTA1, Spectrin Alpha, Erythrocytic 1, Spectrin Alpha Chain, Erythrocytic 1, Erythroid Alpha-Spectrin, Elliptocytosis 2, SPTA, EL2, Spectrin, Alpha, Erythrocytic 1 (Elliptocytosis 2), Spectrin Alpha Chain, Erythrocyte, Alpha-I Spectrin, SPTA1, SPH3, HPP, HS3
    Entrez ID:
    6708
    Related biomarkers:
    Mutation
    2years
    PIK3CA somatic mutations as potential biomarker for immunotherapy in elder or TP53 mutated gastric cancer patients. (PubMed, Clin Genet)
    For the first time, we found that GC patients ?60?years old or with TP53 mutated type and PIK3CA mutations were associated with higher TMB and better ICI response. Building upon the age and TP53 mutation status, this study suggested a novel stratification approach to GC patients and explored the correlations between genetic somatic mutations and TMB score.
    Journal • Tumor Mutational Burden • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • ARID1A (AT-rich interaction domain 1A) • LRP1B (LDL Receptor Related Protein 1B) • KMT2C (Lysine Methyltransferase 2C) • CDH1 (Cadherin 1) • SPTA1 (Spectrin Alpha)
    |
    TP53 mutation • TMB-H • HER-2 amplification • PIK3CA mutation • ARID1A mutation • SPTA1 mutation
    almost3years
    Comprehensive analysis and potential clinical applications of immunotherapy-related biomarkers in Chinese patients with pancreatic adenocarcinoma (AACR 2022)
    We described the characteristics of TMB, MSI and PD-L1 expression in Chinese patients with PAC. In the absence of HP related mutations, comprehensive consideration of TMB, MSI and PD-L1 status may guide PAC immunotherapy and benefit PAC patients.
    Clinical • Tumor Mutational Burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ATM (ATM serine/threonine kinase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • SMAD4 (SMAD family member 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • SPTA1 (Spectrin Alpha)
    |
    PD-L1 expression • TP53 mutation • KRAS mutation • TMB-H • MSI-H/dMMR • ATM mutation • PD-L1 negative • SPTA1 mutation
    over3years
    [VIRTUAL] Identification of predictive biomarker for immunotherapy by associating with CD8+T cell Infiltration in lung adenocarcinoma. (ASCO 2021)
    Our data show that it is feasible to identify individuals or groups of individual with specific mutations to immunotherapy responses from TIME view . SPTA1mt was a core predictors for higher CD8+ TILs and can be identified as a predictive biomarker for benefit from I/O compared with CT . Prospective studies are warranted for further investigation.
    IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • KEAP1 (Kelch Like ECH Associated Protein 1) • CD8 (cluster of differentiation 8) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) • SPTA1 (Spectrin Alpha) • HSD3B1 (Hydroxy-Delta-5-Steroid Dehydrogenase 3 Beta- And Steroid Delta-Isomerase 1) • STAT4 (Signal Transducer And Activator Of Transcription 4)
    |
    KEAP1 mutation • SPTA1 mutation